Ron Dagan1, Christine Juergens2, James Trammel3, Scott Patterson4, David Greenberg5, Noga Givon-Lavi6, Nurith Porat7, William C Gruber8, Daniel A Scott9. 1. The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel. Electronic address: rdagan@bgu.ac.il. 2. Pfizer Pharma GmbH, Linkstrasse 10, 10785 Berlin, Germany. Electronic address: Christine.Juergens@pfizer.com. 3. inVentiv Health Clinical, 504 Carnegie Center, Princeton, NJ 08540, USA. Electronic address: james.trammel@inventivhealth.com. 4. Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA. Electronic address: Scott.Patterson@Pfizer.com. 5. The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel; The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel. Electronic address: dudi@bgu.ac.il. 6. The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel; The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel. Electronic address: givon@bgu.ac.il. 7. The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel; The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel. Electronic address: npurat@bgu.ac.il. 8. Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA. Electronic address: Bill.Gruber@Pfizer.com. 9. Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA. Electronic address: Dan.Scott@Pfizer.com.
Abstract
BACKGROUND: A prior 7- and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13) study provided sufficient data (N=1754; Jewish, n=1154; Bedouin, n=595; other, n=5) to investigate the association between nasopharyngeal (NP) acquisition of common PCV7 serotypes and cross-reacting 6A (PCV7+6A) and IgG concentrations. METHODS: Using a logistic regression model, serotype specific association between postinfant series IgG concentration (age 7months) and new NP acquisition between ages 7 and 24months was assessed and adjusted for ethnicity. From a subset of subjects with new NP acquisition (n=9-152 across serotypes studied), new acquisition percentiles and associated IgG concentrations were calculated. RESULTS: For the serotypes studied, new NP acquisition rates decreased as IgG concentrations increased. Ethnicity did not influence these associations despite differences in carriage rates. From the subset with new acquisitions, 50% of the events occurred at IgG concentrations >0.61-5.58μg/mL; and 10% of the acquisitions occurred at IgG concentrations >2.48-17.69μg/mL. CONCLUSION: Remarkably high IgG concentrations are required to reduce NP acquisition. These IgG concentrations differ between serotypes. Ethnicity did not influence the association between high IgG concentrations and prevention of carriage despite differences in carriage rates. Since carriage determines transmission, these results may have important implications for herd protection. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00508742; http://clinicaltrials.gov/ct2/show/NCT00508742.
BACKGROUND: A prior 7- and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13) study provided sufficient data (N=1754; Jewish, n=1154; Bedouin, n=595; other, n=5) to investigate the association between nasopharyngeal (NP) acquisition of common PCV7 serotypes and cross-reacting 6A (PCV7+6A) and IgG concentrations. METHODS: Using a logistic regression model, serotype specific association between postinfant series IgG concentration (age 7months) and new NP acquisition between ages 7 and 24months was assessed and adjusted for ethnicity. From a subset of subjects with new NP acquisition (n=9-152 across serotypes studied), new acquisition percentiles and associated IgG concentrations were calculated. RESULTS: For the serotypes studied, new NP acquisition rates decreased as IgG concentrations increased. Ethnicity did not influence these associations despite differences in carriage rates. From the subset with new acquisitions, 50% of the events occurred at IgG concentrations >0.61-5.58μg/mL; and 10% of the acquisitions occurred at IgG concentrations >2.48-17.69μg/mL. CONCLUSION: Remarkably high IgG concentrations are required to reduce NP acquisition. These IgG concentrations differ between serotypes. Ethnicity did not influence the association between high IgG concentrations and prevention of carriage despite differences in carriage rates. Since carriage determines transmission, these results may have important implications for herd protection. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00508742; http://clinicaltrials.gov/ct2/show/NCT00508742.
Authors: Marc Lipsitch; Lucy M Li; Scott Patterson; James Trammel; Christine Juergens; William C Gruber; Daniel A Scott; Ron Dagan Journal: Vaccine Date: 2017-12-14 Impact factor: 3.641
Authors: Beth Temple; Nguyen Trong Toan; Vo Thi Trang Dai; Kathryn Bright; Paul Vincent Licciardi; Rachel Ann Marimla; Cattram Duong Nguyen; Doan Y Uyen; Anne Balloch; Tran Ngoc Huu; Edward Kim Mulholland Journal: Lancet Infect Dis Date: 2019-04-08 Impact factor: 25.071